Matrix Metalloproteinases as Drug Targets in Preeclampsia

Author(s): Ana C.T. Palei, Joey P. Granger, Jose E. Tanus-Santos

Journal Name: Current Drug Targets

Volume 14 , Issue 3 , 2013

Become EABM
Become Reviewer
Call for Editor


Preeclampsia is an important syndrome complicating pregnancy. While the pathogenesis of preeclampsia is not entirely known, poor placental perfusion leading to widespread maternal endothelial dysfunction is accepted as a major mechanism. It has been suggested that altered placental expression of matrix metalloproteinases (MMPs) may cause shallow cytotrophoblastic invasion and incomplete remodeling of the spiral arteries. MMPs are also thought to link placental ischemia to the cardiovascular alterations of preeclampsia. In fact, MMPs may promote vasoconstriction and surface receptors cleavage affecting the vasculature. Therefore, the overall goal of this review article is to provide an overview of the pathophisiology of preeclampsia, more specifically regarding the role of MMPs in the pathogenesis of preeclampsia and the potential of MMP inhibitors as therapeutic options.

Keywords: Hypertension, hypertensive disorders, matrix metalloproteinases, preeclampsia, pregnancy, therapy, Chronic hypertension, Gestational hypertension, CARDIOVASCULAR ADAPTATIONS, renin-angiotensin-aldosterone system (RAAS)

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2013
Published on: 27 January, 2013
Page: [325 - 334]
Pages: 10
DOI: 10.2174/1389450111314030004
Price: $65

Article Metrics

PDF: 13